" class="no-js "lang="en-US"> Gensaic to Develop a Gene Therapy for People with Cystic Fibrosis
Thursday, December 12, 2024

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Gensaic Receives Funding From the CF Foundation to Develop a Gene Therapy for People With Cystic Fibrosis | PTF

January 10 2023

Gensaic Receives Funding From the CF Foundation to Develop a Gene Therapy for People With Cystic Fibrosis

Gensaic, a company that seeks to reimagine gene therapy, has announced that it has received an investment from the CF Foundation to develop a gene therapy for Cystic Fibrosis (CF).

“The investment by the CF Foundation is a recognition of the alignment between Gensaic’s and the CF Foundation’s mission. Together, we hope to bring forward a gene therapy to treat the underlying cause of this devastating disease for all patients with Cystic Fibrosis,“ said Lavi Erisson, MD, MPH, MBA, co-founder, and CEO of Gensaic. “Working with the CF foundation represents an incredible opportunity for Gensaic to lean into the CF Foundation’s leadership in fundamental research, patient advocacy, and therapeutic development”.

Under the terms of the 1st tranche, Gensaic will harness its proprietary PDP platform to achieve pre-clinical milestones upon which the 2nd tranche will be transacted. Gensaic will retain all rights to the continued development of a lead program.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

    Clinical Trials

     Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS

    Clinical Trials

     Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board

    Appointments

     Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera

    News

     Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic

    Clinical Trials

     Read more
More On